ArticleCureus2025
A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-Hodgkin lymphoma (NHL) is one of the most common malignancies worldwide. Although the incidence rate is relatively low in Saudi Arabia, the disproportionately high mortality rate highlights the need for local studies addressing the disease characteristics and prognostic factors Methods: This was a retrospective study conducted at a tertiary care hospital in Riyadh, Saudi Arabia. Data from 252 patients diagnosed with NHL between 2017 and 2022 were reviewed and collected from electronic medical records. The variables included patients' demographics and clinical characteristics. IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, New York, United States) was used for data entry and analysis. Survival outcomes were analysed using Kaplan-Meier curves, and differences between groups were evaluated using log-rank tests. A p-value of ≤ 0.05 was considered statistically significant.
resultsDiffuse large B-cell lymphoma (DLBCL) accounted for 179 (71%) cases, making it the most common type, followed by follicular NHL (FNHL), which accounted for 34 (13.5%). Almost half of the patients (n=123, 48.8%) presented at stage IV, which was associated with poor survival (p<0.0001). Bone marrow involvement was found in 75 (28.6%) patients and was associated with shorter survival (p=0.002). Patients who did not survive had a low albumin (32.9 ±6.3 vs 37.6 ±9.7) and increased lactate dehydrogenase (547± 34 vs 227±10) compared to those who were alive. Although younger age groups had longer survival than older patients, the differences did not achieve statistical significance.
conclusionsThis study provides valuable data on NHL patterns and prognosis, highlighting the critical role of early detection and the value of simple laboratory markers in predicting prognosis and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.